Neoadjuvant Immunotherapy in Early Breast cancer
Measuring Lymphocyte Count May Predict Response to CAR T-Cell Therapy in Multiple Myeloma
FDA Approves Perioperative OPDIVO® in Resectable Lung Cancer
Ivonescimab may be Superior to Pembrolizumab as First-Line Treatment in NSCLC
Optimal Approach for Integrating Immune Checkpoint Inhibitors in Early-Stage Breast Cancer: A Meta-Analysis
Immune Checkpoint Inhibitor Therapy and Cardiovascular Adverse Events
Five Year Outcomes with First Line OPDIVO® plus YERVOY® and a Limited Course of Chemotherapy
Late Breaking Abstract – ASCO 2024: Sustained Improvement in Relapse Free Survival with Personalized mRNA Cancer Vaccine plus KEYTRUDA® in Resected High Risk Melanoma
FDA Approves Bispecific T-Cell Engager IMDELLTRA® for Small Cell Lung Cancer
FDA Approves BREYANZI® for Relapsed/Refractory Follicular Lymphoma
Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric and GEJ Cancer Regardless of PD-L1 Status
Benefits of Neoadjuvant Chemoimmunotherapy in Early Stage Non Small Cell Lung Cancer
Cardiovascular Adverse Events Associated with Bispecific T-cell Engager Therapy
FDA Approves BREYANZI®, First CAR-T Cell Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
FDA Approves TEVIMBRA® for Advanced Esophageal Squamous Cell Carcinoma
Circulating Tumor DNA Can be Used as an Early Marker of Immunotherapy Response
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Adjuvant KEYTRUDA® Improves Overall Survival in Renal cell Carcinoma
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Subcutaneous Nivolumab Offers Efficiency and Efficacy in Renal Cell Carcinoma
FDA Approves KEYTRUDA® with Chemotherapy for HER2-Negative Gastric or GE Junction Adenocarcinoma
FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer